The AI-biotech field has operated for years on a credibility deficit not of its own making — the tools improved faster than the trials could confirm them. Rentosertib changed that calculus. Insilico Medicine's Phase IIa data showed measurable improvement in lung function for idiopathic pulmonary fibrosis patients after twelve weeks [15], and the significance is not just therapeutic. It is structural: a trial result from a fully AI-designed compound gives every subsequent funding announcement a different evidentiary footing. The week that followed — Excelsior's raise , Boltz-2's release , Harvard's…